VMC si iseatsacdo wthi nigteicnf anrgo stltprnaan pnistta.e MVC si nidttamsret avi xeauls tt,canco agrno lpaansr,tnt or telirylavc iav n.aplceat ivoanactiRet fo MCV scrouc in eht eud.smpsormeinusp
nOagr asnntltrpa iestpnat era ta na iserandec iskr fo CVM u.peminona
eh saw eevrn gnvei ioingclrvca - i sdeu ttah as a ulce oevr altntnrspa enrijotec
Wyh oulwd tish not eb tcuae tanrnatspl ritcjnoee gedalni to AD?RS eTh acrinetein is laveet,ed dan I ese any eonsra why ti dowul eb ateldeev nodeby netiojecr
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir
or ganciclovir
is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by ∗amorah(115)
It can be re-accessed by making a purchase.
Purchase your membership here
$279$49rFeve t&-g; eurl tou ltfe evrcalntiru ruaelif MMXS-TP ysrplhiaopx ;&-tg rule tou Pnmuotssciye eiicijyoKenrd v nratlpatsn tub no WBBCR/C ni uienr &;-tg leru uot natntprasl nocjirete
Legvain VMC nda aaciyptl raieommubytcc as eth mnargniie wto isoont.p MVC is mroe ekylli in a astantnrpl .tipnate
$279$49